Noncontrast Radiomics Approach for Predicting Grades of Nonfunctional Pancreatic Neuroendocrine Tumors
Background Endoscopic ultrasound‐guided fine‐needle aspiration is associated with the accurate determination of tumor grade. However, because it is an invasive procedure there is a need to explore alternative noninvasive procedures. Purpose To develop and validate a noncontrast radiomics model for t...
Saved in:
Published in | Journal of magnetic resonance imaging Vol. 52; no. 4; pp. 1124 - 1136 |
---|---|
Main Authors | , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
Hoboken, USA
John Wiley & Sons, Inc
01.10.2020
Wiley Subscription Services, Inc |
Subjects | |
Online Access | Get full text |
Cover
Loading…
Summary: | Background
Endoscopic ultrasound‐guided fine‐needle aspiration is associated with the accurate determination of tumor grade. However, because it is an invasive procedure there is a need to explore alternative noninvasive procedures.
Purpose
To develop and validate a noncontrast radiomics model for the preoperative prediction of nonfunctional pancreatic neuroendocrine tumor (NF‐pNET) grade (G).
Study Type
Retrospective, single‐center study.
Subjects
Patients with pathologically confirmed PNETs (139) were included.
Field Strength/Sequence
3T/breath‐hold single‐shot fast‐spin echo T2‐weighted sequence and unenhanced and dynamic contrast‐enhanced T1‐weighted fat‐suppressed sequences.
Assessment
Tumor features on contrast MR images were evaluated by three board‐certified abdominal radiologists.
Statistical Tests
Multivariable logistic regression analysis was used to develop the clinical model. The least absolute shrinkage and selection operator method and linear discriminative analysis (LDA) were used to select the features and to construct a radiomics model. The performance of the models was assessed using the training cohort (97 patients) and the validation cohort (42 patients), and decision curve analysis (DCA) was applied for clinical use.
Results
The clinical model included 14 imaging features, and the corresponding area under the curve (AUC) was 0.769 (95% confidence interval [CI], 0.675–0.863) in the training cohort and 0.729 (95% CI, 0.568–0.890) in the validation cohort. The LDA included 14 selected radiomics features that showed good discrimination—in the training cohort (AUC, 0.851; 95% CI, 0.758–0.916) and the validation cohort (AUC, 0.736; 95% CI, 0.518–0.874). In the decision curves, if the threshold probability was 0.17–0.84, using the radiomics score to distinguish NF‐pNET G1 and G2/3, offered more benefit than did the use of a treat‐all‐patients or treat‐none scheme.
Data Conclusion
The developed radiomics model using noncontrast MRI could help differentiate G1 and G2/3 tumors, to make the clinical decision, and screen pNETs grade.
Level of Evidence
4
Technical Efficacy Stage
2 J. Magn. Reson. Imaging 2020;52:1124–1136. |
---|---|
Bibliography: | ObjectType-Article-1 SourceType-Scholarly Journals-1 ObjectType-Feature-2 content type line 14 content type line 23 Yun Bian and Zengrui Zhao are the joint first authors in the paper. |
ISSN: | 1053-1807 1522-2586 1522-2586 |
DOI: | 10.1002/jmri.27176 |